Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Radiation Oncology cung cấp cho các bạn kiến thức về ngành y đề tài: Carbon ion therapy for advanced sinonasal malignancies: feasibility and acute toxicity. | Jensen et al. Radiation Oncology 2011 6 30 http content 6 1 30 RADIATION ONCOLOGY RESEARCH Open Access Carbon ion therapy for advanced sinonasal malignancies feasibility and acute toxicity 1 1 2 2 1 Alexandra D Jensen Anna V Nikoghosyan Swantje Ecker Malte Ellerbrock Jurgen Debus and Marc W Munter1 Abstract Purpose To evaluate feasibility and toxicity of carbon ion therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-field local control hence calls for dose escalation which has so far been hampered by accompanying acute and late toxicity. Raster-scanned carbon ion therapy offers the advantage of sharp dose gradients promising increased dose application without increase of side-effects. Methods Twenty-nine patients with various sinonasal malignancies were treated from 11 2009 to 08 2010. Accompanying toxicity was evaluated according to CTCAE . Tumor response was assessed according to RECIST. Results Seventeen patients received treatment as definitive RT 9 for local relapse 2 for re-irradiation. All patients had T4 tumours median CTV1 cc CTV2 cc mostly originating from the maxillary sinus. Median dose was 73 GyE mostly in mixed beam technique as IMRT plus carbon ion boost. Median follow- up was months range - months . There were 7 cases with grade 3 toxicity mucositis dysphagia but no other higher grade acute reactions 6 patients developed grade 2 conjunctivits no case of early visual impairment. Apart from alterations of taste all symptoms had resolved at 8 weeks post RT. Overall radiological response rate was 50 CR and PR . Conclusion Carbon ion therapy is feasible despite high doses acute reactions were not increased and generally resolved within 8 weeks post radiotherapy. Treatment response is encouraging though follow-up is too short to estimate control rates or evaluate potential late effects. Controlled trials
